195 related articles for article (PubMed ID: 29330126)
1. Recent progress in the discovery of myeloid differentiation 2 (MD2) modulators for inflammatory diseases.
Chen L; Fu W; Zheng L; Wang Y; Liang G
Drug Discov Today; 2018 Jun; 23(6):1187-1202. PubMed ID: 29330126
[TBL] [Abstract][Full Text] [Related]
2. Arachidonic acid inhibits inflammatory responses by binding to myeloid differentiation factor-2 (MD2) and preventing MD2/toll-like receptor 4 signaling activation.
Zhang Y; Chen H; Zhang W; Cai Y; Shan P; Wu D; Zhang B; Liu H; Khan ZA; Liang G
Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165683. PubMed ID: 31953218
[TBL] [Abstract][Full Text] [Related]
3. Sulforaphane inhibits the engagement of LPS with TLR4/MD2 complex by preferential binding to Cys133 in MD2.
Koo JE; Park ZY; Kim ND; Lee JY
Biochem Biophys Res Commun; 2013 May; 434(3):600-5. PubMed ID: 23583403
[TBL] [Abstract][Full Text] [Related]
4. Curcumin Analog L48H37 Prevents Lipopolysaccharide-Induced TLR4 Signaling Pathway Activation and Sepsis via Targeting MD2.
Wang Y; Shan X; Dai Y; Jiang L; Chen G; Zhang Y; Wang Z; Dong L; Wu J; Guo G; Liang G
J Pharmacol Exp Ther; 2015 Jun; 353(3):539-50. PubMed ID: 25862641
[TBL] [Abstract][Full Text] [Related]
5. Discovery of caffeic acid phenethyl ester derivatives as novel myeloid differentiation protein 2 inhibitors for treatment of acute lung injury.
Chen L; Jin Y; Chen H; Sun C; Fu W; Zheng L; Lu M; Chen P; Chen G; Zhang Y; Liu Z; Wang Y; Song Z; Liang G
Eur J Med Chem; 2018 Jan; 143():361-375. PubMed ID: 29202400
[TBL] [Abstract][Full Text] [Related]
6. Lipopolysaccharide (LPS) directly suppresses growth hormone receptor (GHR) expression through MyD88-dependent and -independent Toll-like receptor-4/MD2 complex signaling pathways.
Dejkhamron P; Thimmarayappa J; Kotlyarevska K; Sun J; Lu C; Bonkowski EL; Denson LA; Menon RK
Mol Cell Endocrinol; 2007 Aug; 274(1-2):35-42. PubMed ID: 17601656
[TBL] [Abstract][Full Text] [Related]
7. Suppression of Toll-like receptor 4 activation by caffeic acid phenethyl ester is mediated by interference of LPS binding to MD2.
Kim SY; Koo JE; Seo YJ; Tyagi N; Jeong E; Choi J; Lim KM; Park ZY; Lee JY
Br J Pharmacol; 2013 Apr; 168(8):1933-45. PubMed ID: 23231684
[TBL] [Abstract][Full Text] [Related]
8. Discovery of new MD2-targeted anti-inflammatory compounds for the treatment of sepsis and acute lung injury.
Chen G; Xiao B; Chen L; Bai B; Zhang Y; Xu Z; Fu L; Liu Z; Li X; Zhao Y; Liang G
Eur J Med Chem; 2017 Oct; 139():726-740. PubMed ID: 28858767
[TBL] [Abstract][Full Text] [Related]
9. Discovery of new MD2 inhibitor from chalcone derivatives with anti-inflammatory effects in LPS-induced acute lung injury.
Zhang Y; Wu J; Ying S; Chen G; Wu B; Xu T; Liu Z; Liu X; Huang L; Shan X; Dai Y; Liang G
Sci Rep; 2016 Apr; 6():25130. PubMed ID: 27118147
[TBL] [Abstract][Full Text] [Related]
10. Celastrol blocks binding of lipopolysaccharides to a Toll-like receptor4/myeloid differentiation factor2 complex in a thiol-dependent manner.
Lee JY; Lee BH; Kim ND; Lee JY
J Ethnopharmacol; 2015 Aug; 172():254-60. PubMed ID: 26116162
[TBL] [Abstract][Full Text] [Related]
11. The molecular basis of the host response to lipopolysaccharide.
Bryant CE; Spring DR; Gangloff M; Gay NJ
Nat Rev Microbiol; 2010 Jan; 8(1):8-14. PubMed ID: 19946286
[TBL] [Abstract][Full Text] [Related]
12. Heme induces inflammatory injury by directly binding to the complex of myeloid differentiation protein 2 and toll-like receptor 4.
Lin J; Lin K; Huang L; Jiang Y; Ding X; Luo W; Samorodov AV; Pavlov VN; Liang G; Qian J; Wang Y
Toxicol Lett; 2022 Nov; 370():15-23. PubMed ID: 36115635
[TBL] [Abstract][Full Text] [Related]
13. Protective effects of hesperetin on lipopolysaccharide-induced acute lung injury by targeting MD2.
Ye J; Guan M; Lu Y; Zhang D; Li C; Li Y; Zhou C
Eur J Pharmacol; 2019 Jun; 852():151-158. PubMed ID: 30807747
[TBL] [Abstract][Full Text] [Related]
14. Licochalcone A protects against LPS-induced inflammation and acute lung injury by directly binding with myeloid differentiation factor 2 (MD2).
Zhu W; Wang M; Jin L; Yang B; Bai B; Mutsinze RN; Zuo W; Chattipakorn N; Huh JY; Liang G; Wang Y
Br J Pharmacol; 2023 Apr; 180(8):1114-1131. PubMed ID: 36480410
[TBL] [Abstract][Full Text] [Related]
15. Carbon monoxide down-modulates Toll-like receptor 4/MD2 expression on innate immune cells and reduces endotoxic shock susceptibility.
Riquelme SA; Bueno SM; Kalergis AM
Immunology; 2015 Feb; 144(2):321-32. PubMed ID: 25179131
[TBL] [Abstract][Full Text] [Related]
16. New MD2 inhibitors derived from curcumin with improved anti-inflammatory activity.
Zhang Y; Liu Z; Wu J; Bai B; Chen H; Xiao Z; Chen L; Zhao Y; Lum H; Wang Y; Zhang H; Liang G
Eur J Med Chem; 2018 Mar; 148():291-305. PubMed ID: 29466778
[TBL] [Abstract][Full Text] [Related]
17. MD2 mediates angiotensin II-induced cardiac inflammation and remodeling via directly binding to Ang II and activating TLR4/NF-κB signaling pathway.
Han J; Zou C; Mei L; Zhang Y; Qian Y; You S; Pan Y; Xu Z; Bai B; Huang W; Liang G
Basic Res Cardiol; 2017 Jan; 112(1):9. PubMed ID: 28013347
[TBL] [Abstract][Full Text] [Related]
18. Human MD2 deficiency-an inborn error of immunity with pleiotropic features.
Li Y; Yu Z; Schenk M; Lagovsky I; Illig D; Walz C; Rohlfs M; Conca R; Muise AM; Snapper SB; Uhlig HH; Garty BZ; Klein C; Kotlarz D
J Allergy Clin Immunol; 2023 Mar; 151(3):791-796.e7. PubMed ID: 36462957
[TBL] [Abstract][Full Text] [Related]
19. Myeloid differentiation factor 2 in the heart: Bench to bedside evidence for potential clinical benefits?
Sumneang N; Apaijai N; Chattipakorn SC; Chattipakorn N
Pharmacol Res; 2021 Jan; 163():105239. PubMed ID: 33053443
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a New Inhibitor of Myeloid Differentiation 2 from Cinnamamide Derivatives with Anti-Inflammatory Activity in Sepsis and Acute Lung Injury.
Chen G; Zhang Y; Liu X; Fang Q; Wang Z; Fu L; Liu Z; Wang Y; Zhao Y; Li X; Liang G
J Med Chem; 2016 Mar; 59(6):2436-51. PubMed ID: 26937738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
